Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.
Publication Title
Medical oncology (Northwood, London, England)
Document Type
Article
Publication Date
6-8-2023
Keywords
california; psjhc; pacific neurosci; Capicua; Clinical oncology; Glioma; MAPK; Molecular oncology; Targeted medicine; Humans; Oligodendroglioma; Repressor Proteins; Glioma; Mutation; Treatment Outcome; Brain Neoplasms
Abstract
Gliomas are the most prevalent neurological cancer in the USA and care modalities are not able to effectively combat these aggressive malignancies. Identifying new, more effective treatments require a deep understanding of the complex genetic variations and relevant pathway associations behind these cancers. Drawing connections between gene mutations with a responsive genetic target can help drive therapy selections to enhance patient survival. We have performed extensive molecular profiling of the Capicua gene (CIC), a tumor and transcriptional suppressor gene, and its mutation prevalence in reference to MAPK activation within clinical glioma tissue. CIC mutations occur far more frequently in oligodendroglioma (52.1%) than in low-grade astrocytoma or glioblastoma. CIC-associated mutations were observed across all glioma subtypes, and MAPK-associated mutations were most prevalent in CIC wild-type tissue regardless of the glioma subtype. MAPK activation, however, was enhanced in CIC-mutated oligodendroglioma. The totality of our observations reported supports the use of CIC as a relevant genetic marker for MAPK activation. Identification of CIC mutations, or lack thereof, can assist in selecting, implementing, and developing MEK/MAPK-inhibitory trials to improve patient outcomes potentially.
Clinical Institute
Neurosciences (Brain & Spine)
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Neurosciences
DOI
10.1007/s12032-023-02071-0
